Noble Financial Estimates MariMed FY2026 Earnings

MariMed Inc. (OTCMKTS:MRMD) – Analysts at Noble Financial issued their FY2026 earnings per share estimates for shares of MariMed in a research note issued to investors on Monday, March 16th. Noble Financial analyst J. Gomes anticipates that the company will post earnings of ($0.05) per share for the year.

Separately, Zacks Research upgraded shares of MariMed from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. One analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy”.

MariMed Stock Down 1.3%

MRMD opened at $0.08 on Wednesday. The stock’s fifty day simple moving average is $0.09 and its 200 day simple moving average is $0.11. MariMed has a 1-year low of $0.07 and a 1-year high of $0.23. The stock has a market cap of $30.66 million, a PE ratio of -2.58 and a beta of 1.11. The company has a current ratio of 1.00, a quick ratio of 0.38 and a debt-to-equity ratio of 1.44.

About MariMed

MariMed Inc is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.